AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS

Objectives: Acute myeloid leukemia (AML) with fms-like tyrosine kinase 3 (FLT3) mutations account for around 30% of all AML cases. FLT3 is a transmembrane receptor with important roles for hematological cells. The mutations will cause overactivation of signaling pathways such as PI3K, RAS, and STAT5...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	LBL Miranda, NO Rossini, K Lima, DA Pereir-Martins, JJ Schuringa, EM Rego, F Traina, MVB Dias, JA Machad-Neto
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2023-10-01
Saila:	Hematology, Transfusion and Cell Therapy
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2531137923006338
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!